Daily olive oil intake is feasible to reduce trigeminal neuralgia facial pain: A pilot study
Moreno ML, Percival SS, Kelly DL, Dahl WJ
Nutrition research (New York, N.Y.) · 3 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2024-01-10 · Nutr Res · vol. 123 · págs. 101–110
- Editorial
- Elsevier BV
- Citado
- 3 citas · más que el 69% de estudios similares · 0.8× el promedio de su campo
- Referencias
- 78 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Trigeminal Neuralgia and Treatments · Pain Mechanisms and Treatments · Temporomandibular Joint Disorders
- Palabras clave
- extra virgin olive oil, trigeminal neuralgia, facial pain, dietary supplementation, neuroprotection, demyelination, pain intensity, quality of life, dietary adherence, oleic acid, Healthy Eating Index, orofacial function
- MeSH
- humans, trigeminal neuralgia, facial pain, pilot projects, quality of life, adult, female, olive oil
4 autores
- Melissa L. Moreno🇺🇸University of Florida; Institute of Food and Agricultural Sciences
- Susan S. Percival🇺🇸University of Florida; Institute of Food and Agricultural Sciences
- Debra Lynch Kelly🇺🇸University of Florida
- Wendy J. Dahl🇺🇸 · autor de correspondenciaUniversity of Florida; Institute of Food and Agricultural Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Extra virgin olive oil (EVOO) is thought to contribute to neuroprotection and, thus, may influence pain symptoms experienced by adults with demyelination-related trigeminal neuralgia (TN). This study aimed to determine the feasibility of daily intake of EVOO and its potential to alleviate facial pain of TN. Adults, self-reporting as female and affected by TN, were enrolled in a 16-week nonblinded, parallel study. After a 4-week baseline, participants were randomized to 60 mL/day EVOO or control (usual diet and no supplemental EVOO) for 12 weeks. Participants completed a daily questionnaire on pain intensity and compliance, the Penn Facial Pain Scale weekly, the 36-Item Short Form Survey monthly, and dietary assessment during baseline and intervention. Participants (n = 52; 53.3 ± 12.9 years) were recruited nationally; 42 completed the study. The EVOO group, with 90% intake compliance, showed significant decreases in the Penn Facial Pain Scale items of interference with general function, interference with orofacial function, and severity of pain from baseline, whereas the control group showed no improvements. EVOO benefit, compared with control, trended for the interference with orofacial function (P = .05). The 36-Item Short Form Survey items of role limitations resulting from emotional problems and role limitations from physical health favored EVOO. The EVOO group significantly improved their Healthy Eating Index 2015 component scores of fatty acids (primarily from increased oleic acid), sodium, and refined grains. EVOO intake of 60 mL/day was feasible for participants experiencing TN and may mitigate pain and improve quality of life. This trial was registered at clinicaltrials.gov (NCT05032573).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.